Search clinical trials for: eFT508

Total 33 results

Effector Therapeutics

Terminated

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Hepatocellular Carcinoma | Triple Negative Breast Cancer

United States
Effector Therapeutics

Terminated

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Cancer

United States
Effector Therapeutics

Completed

An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)

Castrate-resistant Prostate Cancer (CRPC)

United States
Effector Therapeutics
Pfizer; Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

Microsatellite Stable Relapsed or Refractory Colorectal Cancer

United States
Genfit
Naturalpha; SGS Aster S.A.S.

Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Cardiovascular Diseases | Metabolic Diseases | Diabetes Mellitus, Type 2 | Type 2 Diabetes | Dyslipidemia | Obese

France
Ipsen

Completed

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

Healthy Volunteers

United States
Genfit

Completed

Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

Healthy | Geriatrics

France
Genfit
Premier Research Group plc; Naturalpha

Completed

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

United States, Belgium, France, Germany, Italy, Netherlands, Romania, Spain, United Kingdom
Ipsen

Completed

A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet

Healthy Participants

France
Genfit

Completed

Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.

Impaired Glucose Tolerance | Abdominal Obesity

France
Genfit

Completed

Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Kidney Diseases | Renal Insufficiency | Renal Impairment | Pharmacokinetics

France, Romania
Genfit
University of Miami; Syneos Health

Completed

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

Pharmacokinetics | Hepatic Impairment | Liver Disease

United States
Genfit

Completed

Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

Abdominal Obesity | Atherogenic Dyslipidaemia

France, Romania, Tunisia
Genfit

Completed

Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

Type II Diabetes Mellitus

Bosnia and Herzegovina, Latvia, Macedonia, The Former Yugoslav Republic of, Moldova, Republic of, Romania, Serbia
Extend Biosciences Inc.
National Institutes of Health (NIH); Pharmaceutical Research Associates; Integrated...

Completed

A Phase 1 Study of EXT608 in Healthy Adults

Safety Issues

United States
Genfit

Terminated

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Non Alcoholic Steatohepatitis

United States
Genfit
SGS Life Sciences, a division of SGS Belgium NV

Completed

Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers

Healthy

Belgium
Translational Research in Oncology
Stand Up To Cancer; Effector Therapeutics

Completed

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

Breast Cancer

Canada
Genfit

Completed

Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity

Insulin Resistance | Abdominal Obesity

France
Genfit

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

Nonalcoholic Steatohepatitis (NASH) With Fibrosis

United States, Belgium, Germany, France, Canada, Netherlands, Italy, Switzerland, Finland, Puerto Rico, United Kingdom, Denmark, Spain, Australia, Czechia, Sweden, Romania, Argentina, Portugal, Turkey, Mexico, Colombia, South Africa, ... and more
Genfit

Terminated

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Non-Alcoholic Fatty Liver

Netherlands
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Suspended

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Peritoneal Cancer

United States
Genfit

Completed

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cholangitis (PBC)

United States, United Kingdom, France, Germany, Spain
Effector Therapeutics
Medpace, Inc.; ICON plc

Active, not recruiting

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART)

Non-small Cell Lung Cancer

United States, Australia, Georgia
Ipsen

Recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

United States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
Masonic Cancer Center, University of Minnesota

Withdrawn

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

HIV-1-infection | ART | Interleukin | Cd4+ Lymphocyte Deficiency | Lymphoid Tissue; Infection

United States
Northwestern University
National Cancer Institute (NCI); EFFECTOR Therapeutics, Inc.

Active, not recruiting

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Genfit
Eurofins Optimed; PhinC Development; CardiaBase

Completed

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

Healthy Volunteers

France
Fate Therapeutics

Terminated

FT538 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myeloma | AML, Adult

United States
Masonic Cancer Center, University of Minnesota

Active, not recruiting

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myeloid Leukemia | Monocytic Leukemia

United States
Genfit

Completed

Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

Drug-drug Interaction

France
Fate Therapeutics

Terminated

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Fate Therapeutics

Completed

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States

Search clinical trials for: eFT508

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations